ATLANTA--(BUSINESS WIRE)--

Insights into the effects of Neupro (rotigotine transdermal system) on common non-motor symptoms of Parkinsons disease (PD) were presented today at the 64th AAN Annual Meeting in New Orleans, LA.

A post-hoc analysis of data from five, randomized, double-blind, placebo-controlled trials investigated the effect of rotigotine transdermal system on neuropsychiatric features and fatigue in patients with PD. Improvements were observed with rotigotine transdermal system versus placebo in items assessing apathy, anhedonia, anxiety, anxiety/depression, depression and fatigue. In addition, a post hoc analysis of data from the RECOVER* study investigated the effect of rotigotine transdermal system on pain in patients with PD, and in some patients with pain, improvements were observed with rotigotine transdermal system versus placebo.

Post hoc analyses of large amounts of data like these provide valuable insights into the potential impact of rotigotine on the everyday lives of people with Parkinsons, and signal a need for further study in this area, said Professor Robert Hauser, Director, Parkinson's Disease and Movement Disorders Center, University of South Florida, Tampa, FL.

Results presented below should be viewed in the context of the post-hoc analyses. In addition the p-values reported are exploratory and prospective studies are warranted to confirm these findings.

Summary of PD data presented at AAN 2012

ABSTRACT TITLE: Rotigotine transdermal system improves neuropsychiatric features (apathy, anhedonia, anxiety, and depression) and fatigue in patients with Parkinsons disease: A post-hoc analysis of five double-blind placebo-controlled studies

Post-hoc analysis of five placebo-controlled studies of rotigotine transdermal system in patients with early-PD (SP512, SP513), advanced-PD (PREFER, CLEOPATRA-PD), and PD with unsatisfactory control of early-morning motor symptoms (RECOVER) was conducted*. Individual items assessing apathy, anhedonia, anxiety, anxiety/depression, depression and fatigue were identified from the scales used in these studies - the Non-Motor Symptoms Scale (NMSS), the Beck Depression Inventory (BDI-II), the 39-item Parkinsons Disease Questionnaire (PDQ-39), the 8-item Parkinsons disease questionnaire (PDQ-8) and the 5-item EuroQol Group questionnaire (EQ-5D).

ABSTRACT TITLE: Rotigotine transdermal system improves pain in patients with Parkinsons disease: A post-hoc analysis of patients reporting pain in the RECOVER study

RECOVER* (Randomized Evaluation of the 24-hour Coverage: Efficacy of Rotigotine) was a double-blind, placebo-controlled study (n=287) that demonstrated significant improvements in early-morning motor function and nocturnal sleep disturbance with rotigotine transdermal system.* Secondary efficacy measures in the RECOVER study were the Nocturnal, Akinesia, Dystonia and Cramps Score (NADCS) and exploratory outcome measures included the Likert Pain Scale.

Read the original here:
New Post-Hoc Analyses Examined Neupro® Effects on Pain, Depressed Mood, Apathy and Fatigue in Patients with Parkinson ...